Copyright
©The Author(s) 2015.
World J Clin Oncol. Oct 10, 2015; 6(5): 99-103
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.99
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.99
PFI > 3-6 mo |
> 50% PSA response to first-line docetaxel |
No cumulative docetaxel-toxicity |
Age < 75 yr |
ECOG PS 0-1 |
- Citation: Petrioli R, Francini E, Roviello G. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 2015; 6(5): 99-103
- URL: https://www.wjgnet.com/2218-4333/full/v6/i5/99.htm
- DOI: https://dx.doi.org/10.5306/wjco.v6.i5.99